The Journal of infection · 2025
Surveillance of invasive beta-haemolytic streptococci in Denmark, 2012 to 2023: A nationwide study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Christiansen Cecilie Hviid, Søgaard Kirstine Kobberøe, Dam-Dalgeir Gertrud, Dessau Ram B, Dzajic Esad, Jensen Christian Salgård, Lützen Lisbeth, Pedersen Michael, Skovgaard Sissel, Sydenham Thomas Vognbjerg, Hoffmann Steen, Nielsen Hans Linde
Аннотация
OBJECTIVES: To analyse trends in incidence, seasonality, and antimicrobial resistance of invasive beta-haemolytic streptococci (iBHS) in Denmark from 2012 to 2023.
METHODS: Nationwide laboratory surveillance included submission of invasive isolates of Lancefield group A, B, C, and G streptococci from blood, cerebrospinal fluid, and other sterile sites to the National Reference Laboratory. Incidence rates (IRs) per 100,000 were calculated. Seasonality was analysed using Poisson regression, and antimicrobial susceptibility was determined by EUCAST disc diffusion.
RESULTS: In total, 9470 iBHS cases were identified. Annual IRs increased from 2.6 to 9.4 for iGAS, 2.5 to 4.9 for iGBS, 1.4 to 4.8 for iGCS, and 3.1 to 8.5 for iGGS. iGAS exhibited marked seasonality, peaking in February and troughing in September (peak-to-trough ratio 3.2). Incidence declined during the COVID-19 pandemic but rebounded in 2023. No seasonality was observed for iGBS, iGCS, or iGGS. Incidences were highest in males and older adults, except iGBS, which showed a bimodal distribution. Recurrent infections occurred in 5.4% of cases, predominantly with iGGS and iGCS. All isolates were penicillin susceptible, but erythromycin and clindamycin resistance increased in iGBS and iGGS.
CONCLUSIONS: The rising incidence of iBHS, particularly iGAS resurgence and increasing resistance, highlights the need for continued surveillance.
METHODS: Nationwide laboratory surveillance included submission of invasive isolates of Lancefield group A, B, C, and G streptococci from blood, cerebrospinal fluid, and other sterile sites to the National Reference Laboratory. Incidence rates (IRs) per 100,000 were calculated. Seasonality was analysed using Poisson regression, and antimicrobial susceptibility was determined by EUCAST disc diffusion.
RESULTS: In total, 9470 iBHS cases were identified. Annual IRs increased from 2.6 to 9.4 for iGAS, 2.5 to 4.9 for iGBS, 1.4 to 4.8 for iGCS, and 3.1 to 8.5 for iGGS. iGAS exhibited marked seasonality, peaking in February and troughing in September (peak-to-trough ratio 3.2). Incidence declined during the COVID-19 pandemic but rebounded in 2023. No seasonality was observed for iGBS, iGCS, or iGGS. Incidences were highest in males and older adults, except iGBS, which showed a bimodal distribution. Recurrent infections occurred in 5.4% of cases, predominantly with iGGS and iGCS. All isolates were penicillin susceptible, but erythromycin and clindamycin resistance increased in iGBS and iGGS.
CONCLUSIONS: The rising incidence of iBHS, particularly iGAS resurgence and increasing resistance, highlights the need for continued surveillance.